Research To Practice | Oncology Videos

Featuring perspectives from Ms Marianne Davies, Dr Matthew Gubens, Dr Lowell Hart and Ms Chaely Medley, including the following topics: Introduction (0:00) Overview of Small Cell Lung Cancer (SCLC) (6:42) First-line Therapy and Prevention of Cytopenias (25:03) Second Line and Beyond (1:04:33) SVC (Superior Vena Cava), SIADH (Syndrome of Inappropriate Antidiuretic Hormone) and Other Paraneoplastic Syndromes (1:20:25) Complementary Treatments (1:25:57) NCPD information and select publications

Featuring perspectives from Dr Richard Finn and Ms Amanda Wagner, including the following topics: Introduction (0:00) First-line Treatment of Hepatocellular Cancer (HCC) (2:28) Management of Recurrent HCC (26:57) Treatment of Biliary Tract Cancers (33:39) NCPD information and select publications

Featuring a slide presentation and related discussion from Dr Brian Rini on the role of immunotherapy in nonmetastatic renal cell carcinoma and considerations for disease management in special patient populations. CME information and select publications

Featuring perspectives from Drs Thomas Hutson and Brian Rini, including the following topics: Introduction — Common Questions in the Management of Renal Cell Carcinoma (0:00) Adjuvant Immunotherapy (11:26) First-Line Treatment of Metastatic Disease (27:00) Management of Relapsed/Refractory Disease (38:25) Treatment with Belzutifan (47:35) CME information and select publications

A clinical investigator think tank and enduring multimedia activity with Drs Naval Daver, Stephen Strickland, Geoffrey Uy and Eunice Wang, including the following topics: Introduction to therapy-related Acute Myeloid Leukemia (AML) (0:00) Treatment of AML evolving from prior MDS (12:27) Treatment of secondary AML in a patient ineligible for intensive therapy (29:41) Treatment for a patient with secondary AML with an IDH mutation (40:56) Long-term follow-up of CPX- 351 in patients with secondary AML (46:27) Potential role of venetoclax in combination with intensive chemotherapy regimens (52:54) Treatment for younger patients with secondary AML (58:46) Treatment of secondary AML with a FLT3 mutation (1:03:59) Data with CPX-351 in combination with targeted agents (1:08:30) Refractory disease versus differentiation syndrome from IDH inhibitors (1:19:20) Emerging data with menin inhibitors (1:28:13) Treatment of secondary AML evolving from prior MPN (1:31:52) Treatment of secondary AML with core binding factor (1:53:14) CME information and select publications

Featuring perspectives from Drs Raoul Concepcion, Fred Saad and Matthew Smith, moderated by Dr Emmanuel Antonarakis, including the following topics: Introduction (0:00) Management Approaches for Nonmetastatic Prostate Cancer — Raoul S Concepcion, MD (3:00) Role of Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer — Matthew R Smith, MD, PhD (31:55) Selection and Sequencing of Therapy for Metastatic Castration-Resistant Prostate Cancer — Emmanuel S Antonarakis, MD (1:00:03) Current and Future Integration of PARP Inhibitors in the Management of Prostate Cancer — Fred Saad, MD (1:30:29) CME information and select publications

Featuring perspectives from Dr Justin Gainor, including the following topics: Introduction (0:00) Immunotherapy for Patients with Targetable Mutations (8:02) Case: A man in his early 80s with recurrent, localized spindle cell carcinoma of the lung, PD-L1 of 40% — Kapisthalam (KS) Kumar, MD (16:03) Case: A woman in her late 50s with microsatellite-stable adenocarcinoma of the lung with an NRG1 fusion — Ranju Gupta, MD (26:57) Case: A woman in her late 50s with metastatic PD-L1-negative adenocarcinoma of the lung and a RET KF5B fusion — Neil Morganstein, MD (32:13) Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an ALK rearrangement, PD-L1 of 5% — Susannah Friemel, MD (37:17) Cases: A woman in her early 50s with metastatic NSCLC and an ALK (2p23) rearrangement, PD-L1 tumor proportion score of 50%; a man in his mid 60s with metastatic adenocarcinoma of the lung involving the brain, an ALK rearrangement and PD-L1 of 20% — Daniel R Carrizosa, MD, MS (41:52) Case: A man in his late 60s with metastatic adenocarcinoma of the lung and a HER2 V659D mutation — Spencer Henick Bachow, MD (47:49) CME information and select publications

Featuring perspectives from Drs Matthew Galsky, Ashish Kamat and Stephen Williams, moderated by Dr Sumanta Kumar Pal, including the following topics: Introduction (0:00) Available Data with and Ongoing Investigation of Novel Agents and Strategies for Non-Muscle-Invasive Bladder Cancer (NMIBC) — Ashish M Kamat, MD, MBBS (2:17) Novel Therapeutic Approaches for Muscle-Invasive Bladder Cancer (MIBC) — Stephen B Williams, MD, MS (33:41) Current and Future Front-Line Management of Metastatic Urothelial Bladder Carcinoma (mUBC) — Matthew D Galsky, MD (1:00:55) Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Sumanta Kumar Pal, MD (1:43:07) CME information and select publications

Featuring perspectives from Ms Jennifer Filipi, Dr Kathleen Moore, Dr Krishnansu Tewari and Ms Deborah Wright, including the following topics: Introduction (0:00) Primary Ovarian Cancer: Neoadjuvant and Adjuvant Chemotherapy (11:48) PARP Inhibitor Maintenance Therapy (29:29) Adherence in the Maintenance Setting (1:02:06) Novel Strategies and Clinical Trials (1:15:55) NCPD information and select publications

Featuring perspectives from Dr Yelena Janjigian, including the following topics: Introduction (0:00) Management of HER2-Negative Gastroesophageal Cancers (2:10) Case: A man in his early 60s with HER2-negative metastatic squamous cell carcinoma of the esophagus; PD-L1 70% — Kapisthalam (KS) Kumar, MD (23:56) Case: A man in his late 50s with a history of GERD diagnosed with localized esophageal adenocarcinoma — Gurveen Kaur, MD (26:43) Case: A man in his early 50s with localized gastroesophageal-junction adenocarcinoma — G Richard Polkinghorn, MD (30:05) Case: A man in his early 80s with localized HER2-negative esophageal adenocarcinoma — Raymond Lobins, DO (33:24) Case: A man in his early 80s with HER2-negative metastatic gastric cancer; MSS, PD-L1 CPS 5 — Neil Morganstein, MD (35:44) Treatment for HER2-Positive Gastroesophageal Cancers (44:34) Case: A woman in her mid 60s with metastatic esophageal adenocarcinoma; PD-L1 CPS 5, HER2 amplification — Dr Kaur (49:58) Case: A man in his early 60s with HER2-positive metastatic gastric cancer — Dr Morganstein (53:44) Journal Club with Dr Janjigian (57:37) CME information and select publications